Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Tight bands on legs may boost workout benefits for lung disease patients

NCT ID NCT07668921

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study tests whether using a blood flow restriction (BFR) device during exercise can increase muscle fatigue in people with COPD, potentially making rehab more effective. Forty participants will do one session of resistance or cycling exercise with and without BFR. The goal is to see if BFR helps build muscle while reducing breathing strain.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood flow restriction device
What this could lead to
If it works, this could point toward a more effective exercise program for people with COPD, helping them get stronger with less strain on their breathing.
What could go wrong
This is a very early, small study (40 people) looking only at immediate effects after a single session. It does not test long-term benefits or safety, and results may not apply to all COPD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Negative pregnancy test and use of an acceptable contraceptive method throughout the study duration for women of childbearing potential * Established COPD defined as obstructive ventilatory defect (FEV1/FVC \< 0.70 or below the 5th percentile) * Resting lung hyperinflation defined as functional residual capacity \> 2.5 z-scores according to the Global Lung Function Initiative (GLI) * Clinical stability of COPD for at least 3 months, with no recent exacerbation requiring treatment modification * Covered by a national health insurance system * Able and willing to provide written informed consent Non-inclusion Criteria: * Presence of a medical device incompatible with magnetic stimulation * Inability to perform an exercise test on a cycle ergometer * Any usual contraindication to exercise testing, including: * Recent myocardial infarction (3-5 days) * Unstable coronary insufficiency * Severe stenotic valvular disease * Uncontrolled arrhythmia with hemodynamic instability * Recent unexplained syncope * Uncontrolled heart failure * Uncontrolled arterial hypertension (systolic blood pressure ≥200 mmHg and/or diastolic blood pressure ≥110 mmHg at rest) * Acute thromboembolic disease and/or pulmonary edema * Conditions contraindicating the use of blood flow restriction (BFR), including: * Coagulation disorder * Peripheral neuropathy * Uncontrolled hypertension (\>160/100 mmHg) * Peripheral arterial disease * History of venous thrombosis * Intensive care unit stay within the last 3 months * Participation in another study during an exclusion period * Inability to be contacted in case of emergency * Individuals covered under Articles L1121-5 to L1121-8 of the French Public Health Code (protected populations, including pregnant or breastfeeding women, prisoners, minors, individuals under legal protection, psychiatric inpatients, etc.) * Staff members with a hierarchical relationship with the principal investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood flow restriction training (BFRT) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CReSI - Laboratoire HP2

    La Tronche, Auvergne-Rhône-Alpes, 38700, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.